Patents Assigned to WntRx Pharmaceuticals Inc.
  • BCL9 peptides and variants thereof
    Patent number: 11591365
    Abstract: Disclosed here are polypeptides derived from the HD2 domain of human B-cell CLL/lymphoma 9 (BCL9) protein and variants thereof, as well as their use in the diagnosis, prevention, and/or treatment of a disease or disorder. Also disclosed are methods of generating such polypeptides and variants thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: February 28, 2023
    Assignee: WntRx Pharmaceuticals Inc.
    Inventors: David Zhu, Robert Perni, Yvonne Angell
  • Stabilized BCL9 peptides for treatment of aberrant WNT signaling
    Patent number: 11498947
    Abstract: Methods for treating cancer with a stabilized BCL9 peptide are encompassed, wherein the stabilized peptide comprises a portion of the HD2 domain of the BCL9 protein containing a hydrocarbon crosslinker generated using ?, ?-disubstituted amino acids.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: November 15, 2022
    Assignee: WntRx Pharmaceuticals Inc.
    Inventor: David Zhu
  • Stabilized BCL9 peptides for treatment of aberrant WNT signaling
    Patent number: 10961290
    Abstract: Methods for treating cancer with a stabilized BCL9 peptide are encompassed, wherein the stabilized peptide comprises a portion of the HD2 domain of the BCL9 protein containing a hydrocarbon crosslinker generated using ?, ?-disubstituted amino acids.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 30, 2021
    Assignee: WntRx Pharmaceuticals Inc.
    Inventor: David Zhu